CHANGES OF PLATELET HEMOSTASIS PARAMETERS IN PATIENTS WITH HYPERTENSION COMBINED COURSE OF COPD IN THE DYNAMICS OF HOSPITAL TREATMENT PERIOD

Abstract

The combination of arterial hypertension (AH) and chronic obstructive pulmonary disease (COPD) is often encountered in clinical practice. To determine the state of functional activity of platelets in patients with AH in conjunction with COPD before and after of a comprehensive treatment we examined 150 people: 15 healthy (control), 36 patients with COPD ll-lll without AH (I group), 69 AH patients with concomitant COPD (group II) and 30 patients with stage 2 AH (group III). In the treatment of patients with essential hypertension and comorbidity were further divided into 2 groups, depending on the assigned antihypertensive treatment. One patient was assigned lisinopril 10 mg 1 time a day, the second - amlodipine 10 mg 1 per day.We have determined that in patients with arterial hypertension, COPD and when combined an increase of the functional activity of platelets, which manifests itself in increasing the degree of spontaneous aggregation, a significant activation of arachidonic acid induced platelet aggregation. Appointment of ACE inhibitors as antihypertensive treatment in patients with combined ofAH and COPD reduces the spontaneous aggregation and AK-induced aggregation. Treatment of patients with comorbidity using CCB reduces the spontaneous and ADP-induced aggregation. In applying the combined treatment of patients with combined ofAH and COPD with the use of ACE inhibitors and CCBs should expect a significant positive impact on platelet function, which will manifest itself in reducing spontaneous, ADP-induced and AK- induced platelet aggregation.

Keywords

• hypertension, chronic obstructive pulmonary disease, hemostasis, platelet aggregation inhibitors, angiotensin-converting enzyme (ace inhibitors), calcium channel blockers (ccbs).